63
Participants
Start Date
July 14, 2023
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2026
Guselkumab
Guselkumab (GUS) subcutaneous injection
Golimumab
Golimumab (GOL) subcutaneous injection
RECRUITING
New York University, New York
RECRUITING
Hospital at the University of Pennsylvania, Philadelphia
RECRUITING
Parris and Associates, Lilburn
RECRUITING
Family Arthritis Center, Loxahatchee Groves
RECRUITING
Healing Rheumatology, Plant City
RECRUITING
Southwest Florida Rheumatology, Riverview
RECRUITING
Cumberland Rheumatology, Crossville
RECRUITING
Cincy Arthritis, Blue Ash
RECRUITING
Southern Ohio Rheumatology, Wheelersburg
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
Heritage Rheumatology and Arthritis Care, Colleyville
RECRUITING
Texas Arthritis Center, El Paso
RECRUITING
University of Utah, Salt Lake City
RECRUITING
University of Massachusetts Chan Medical School, Worcester
Janssen Scientific Affairs, LLC
INDUSTRY
University of Pennsylvania
OTHER